SAN FRANCISCO, Nov. 3 /PRNewswire-FirstCall/ -- Vista Partners announced today that it has initiated coverage on Inovio Biomedical Corporation (AMEX:INO). Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. Ross Silver of Vista Partners issued the report. For more information and to download the report; please visit the Vista Partners website at http://www.vistap.com/ .
Inovio Biomedical Corporation is a late stage biomedical company focused on commercializing a cancer ablation therapy and development of multiple DNA vaccines with its delivery platform for gene-based treatments. Inovio's Selective Electrochemical Tumor Ablation (SECTA) therapy is designed to locally treat solid tumors, with highly selective killing of cancer cells while preserving surrounding healthy tissue. Inovio is moving its MedPulser(R) product through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark accreditation, a U.S. Phase III pivotal study for head and neck cancer, and a Phase I trial for breast cancer. Merck, Vical, University of Southampton and H. Lee Moffitt Cancer Center are conducting phase I clinical studies of DNA vaccines and immunotherapies using Inovio's electroporation-based DNA delivery technology. Innogenetics and Pharmexa are conducting DNA vaccine clinical studies using the company's recently acquired DNAvax(R) technology. Inovio is a leader in developing human therapeutic applications of electroporation and DNA vaccination, with the industry's most extensive patent portfolio covering in vivo electroporation.
Contact:
Vista Partners LLC
Ross Silver, Jeremy Thum
(415) 738-6229
http://www.vistap.com/ DATASOURCE: Vista Partners LLC CONTACT: Ross Silver or Jeremy Thum both of Vista Partners LLC, +1-415-738-6229, or Web site: http://www.vistap.com/
|